Akorn Extends Natco Agreement
Posted on: Friday, 3 November 2006, 12:00 CST
Akorn has added two injectable drug products to its API supply and margin sharing agreement with Natco Pharma.
The two drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, and have a combined current market size of approximately $360 million.
Under the agreement that was in signed April 2006, Natco will be responsible for the supply of active pharmaceutical ingredients for both drug products. Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the US and Canada.
"These two products will provide an excellent fit with our oncology product pipeline," stated Arthur Przybyl, Akorn's president and CEO
"We are happy to take our cooperation to four projects now. This deal structure will enhance business opportunities in an increasingly competitive environment," said Rejeev Nannapaneni, Natco Pharma's COO.
Source: Datamonitor
Related Articles
- Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
- Akorn Signs Commercial Manufacturing Supply Agreement
- Scientists Create New Way to Make Drugs
- Akorn and Natco Expand Supply Agreement
- Nutrition 21 Receives Commitment From Duane Reade for Its Chromax(R) and Diachrome(R) Products; Food, Drug and Mass Retailer Support Continues to Grow
- Akorn and Natco Collaborate on Generic Drugs
- Drug Prices Rise in Vietnam
- FDA Promises to Expedite Bird-Flu Drug
- FDA to Expedite Bird-Flu Drug
 |
 |
User Comments (0)
RSS Feeds